Long non-coding RNA H19 regulates proliferation of ovarian granulosa cells via STAT3 in polycystic ovarian syndrome

Li Li, Jianxun Wei, Jiangrong Hei, Yongbian Ren, Hongmei Li

Department of Obstetrics, Yanan University Affiliated Hospital, Yan'an, China

Submitted: 14 May 2019
Accepted: 18 July 2019

Arch Med Sci
DOI: https://doi.org/10.5114/aoms.2019.89254
Copyright © 2019 Termedia & Banach

Abstract

Introduction: Studies have shown that long non-coding RNAs (lncRNA) are aberrantly expressed in polycystic ovarian syndrome (PCOS) ovaries and may have a role in PCOS development. In this study, the role and therapeutic implications of lncRNA H19 were investigated in PCOS ovaries and granulosa cells.

Material and methods: qRT-PCR was used for expression analysis. Cell Counting Kit 8 (CCK-8) assay was used for cell viability and acridine orange/ethidium bromide (AO/EB) and Annexin V/propidium iodide staining was used to detect apoptosis. All transfections were carried out with Lipofectamine 2000 reagent. Western blot analysis was used for protein expression analysis.

Results: The expression of lncRNA H19 was remarkably upregulated in the PCOS ovarian tissues as well as the granulosa cells. Suppression of lncRNA H19 expression caused the inhibition of KGN granulosa cell proliferation due to the triggering of apoptosis. Bioinformatic analysis revealed the presence of the GAS binding site for STAT3 in the promoter of lncRNA H19. Silencing of STAT3 suppressed the expression of lncRNA H19 in KGN cells and also halted their growth by triggering apoptosis. Co-transfect experiments revealed that STAT3 and lncRNA H19 silencing cause inhibition of KGN growth synergistically.

Conclusions: lncRNA H19 regulates the growth of ovarian granulosa cells and might prove to be a therapeutic target for management of PCOS.

Key words: polycystic ovarian syndrome, lncRNA H19, apoptosis, STAT3.

Introduction

Studies have shown that a very small portion of the enormous human genome codes for proteins. The major portion of the human genome does not code for proteins or may be involved in the transcription of non-coding RNAs [1]. Mostly, the non-coding RNAs are categorized as long chain or short non-coding RNAs based on transcript size [2]. During the last several decades, a lot of research has been dedicated to the exploration of the functional roles of microRNAs (miRNAs) owing to their diverse functions [3]. However, in the recent past long non-coding RNAs (lncRNAs), which are generally more than 200 nucleotides in length, have also gained importance due to their roles in a variety of processes [4]. LncRNAs have been shown to be aberrantly expressed in different diseases and are now believed to exhibit the potential to act as therapeutic targets.
Many lncRNAs have been reported to be involved in the development of severe diseases such as cancer. For instance, enhanced expression of lncRNA H19 has been shown to be associated with the metastasis of gastric cancer [6]. Moreover, the lncRNA HOTAIR has been shown to be associated with development of cervical cancer [7]. Some lncRNAs have also been shown to regulate drug resistance in thyroid cancer [8]. LncRNAs have also been implicated in the development of several gynecological diseases [9]. Studies have shown several lncRNAs to be aberrantly expressed in the ovaries of patients with polycystic ovarian syndrome (PCOS) [10]. In a recent study, suppression of lncRNA SRA was reported to attenuate PCOS in mice [11]. Similarly, lncRNA LINC-01572 has been shown to suppress the growth of ovarian granulosa cells of PCOS patients [12]. Moreover, lncRNA SRA has been shown to be associated with the development of PCOS [13]. Given these study findings, it is believed that lncRNAs might act as therapeutic targets for the management of PCOS. PCOS is one of the prevalent endocrine disorders involving hyperandrogenism, insensitivity to insulin and oligo-ovulation [14, 15]. It affects approximately 10% of reproductive women, generally causing infertility [16]. There is concrete evidence that suggests that PCOS increases the risk of type 2 diabetes mellitus [17]. Furthermore, studies have shown that although women exhibiting mild forms of PCOS tend to show normal ovulation, the disorder becomes chronic with time if it remains untreated [18]. PCOS is also associated with increased androgen activity and often interferes with the biosynthesis of estrogen and progesterone [19]. Although insulin sensitizers such as metformin are used for the management of PCOS, such drugs are accompanied by adverse effects that negatively affect the quality of life of patients [20].

Therefore, studies are being directed to identify the molecular mechanisms underlying PCOS to identify the therapeutic targets for the complete treatment of PCOS. The main objective of the present study was to study the role and therapeutic potential of lncRNA H19 in PCOS.

Material and methods

Tissues and cell lines

PCOS ovarian and normal ovarian tissues were obtained from 15 women with PCOS and 15 nor-
mal women undergoing laparoscopy or hysterectomy at the Department of Gynecology, Harbin Medical University Cancer Hospital, China. Informed consent was obtained a priori from all the women. All the women were in the same phase of the menstrual cycle and the mean age for normal and PCOS women was 32 years old and 33.5 years old, respectively. PCOS diagnosis was made as described previously [21]. The ovarian granulosa KGN cell line and the normal ovarian cell line SV40 were obtained from the Cell Bank of the Chinese Academy of Science (Shanghai, China). The KGN cell line has also been used previously for the study of PCOS [22]. All transfections were carried out using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) as per the manufacturer’s protocol. The study was approved by the research ethics board of Yanan University Affiliated Hospital, Yan’an, 716000, China under approval number YU/DO/324 of 2018.

qRT-PCR analysis

Trizol reagent (Invitrogen) was employed to extract RNA from the tissue samples as well as the cell lines. M-MLV reverse transcriptase was used for the synthesis of DNA which was later amplified by SYBR Green master mix (Invitrogen). Expression was assessed by qRT-PCR with actin as an internal control. The cycling conditions were as follows: 95°C for 20 s, followed by 40 cycles of 95°C for 15 s, and 58°C for 1 min.

Cell viability assay

The Cell Counting Kit 8 (CCK-8) was used to examine the viability of the KGN cells. The KGN cells were firstly transfected with appropriate constructs and then cultured for 24 h at 37°C. About 8 µl of CCK-8 solution was added to the cells and again incubated for 2 h. Finally the absorbance was taken at 450 nm at various time points (0, 12, 24, 48 and 96 h).

![Figure 2](image)

**Figure 2.** Silencing of long non-coding (lncRNA) H19 in KGN cells triggers apoptosis as depicted by (A) acridine orange/ethidium bromide (AO/EB) staining and (B) Annexin V/propidium iodide (PI) staining of normal or Si-H19 transfected KGN cells. The experiments were performed in triplicate.
Apoptosis assays

Apoptosis was detected by AO/EB staining. The KGN cells were transfected with appropriate constructs and then cultured in six-well plates for 24 h. Around 5–10 µl of culture was taken on the cover slips and stained with AO/EB solution and observed under a microscope for determination of the percentage of apoptosis. The transfected KGN cells were stained with annexin V/PI and subsequently examined by a flow cytometer as described previously [23].

Western blotting

The KGN cells were cultured for 24 h and then collected by the process of centrifugation. Afterwards the cells were lysed by RIPA buffer and the protein content was determined by BCA assay. An equal amount of protein from each sample was loaded on the SDS-PAGE and separated. Thereafter it was transferred to polyvinylidene fluoride membranes which were then treated with TBS and subsequently incubated with primary antibody at 4°C. This was followed by incubation with appropriate secondary antibody, and visualization of the bands of interest was carried out using an enhanced chemiluminescence reagent.

Statistical analysis

The experiments were repeated three times. Student’s t-test was used for statistical analysis. Values of \( p < 0.05 \) were considered statistically significant.

Results

LncRNA H19 was upregulated in granulosa cells of PCOS ovaries

The transcript levels of lncRNA H19 were evaluated in 15 normal and 15 PCOS ovarian tissues. It was revealed that the expression of lncRNA H19 was remarkably increased in the PCOS ovarian tissues. The expression of H19 was around 3-fold higher in PCOS ovarian tissues compared to normal tissues (Figure 1 A). The expression of H19 was also examined in ovarian granulosa-like KGN cells as well as normal SV40 cells. It was found that the expression of lncRNA H19 was increased in the KGN cells by 3.5-fold (Figure 1 B).

Silencing of H19 inhibited proliferation of KGN cells via apoptosis induction

To ascertain the role of H19 in PCOS ovarian granulosa-like KGN cells, the lncRNA H19 expression

Figure 3. A – Identification of GAS binding sequence for STAT3 in the promoter of long non-coding RNA (lncRNA) H19. B – Western blots showing expression of STAT3 in normal (NC) and Si-STAT3 transfected KGN cells. C – Expression of lncRNA H19 and STAT3 in NC and Si-STAT3 transfected KGN cells as depicted by qRT-PCR. The values represent the mean of 3 replicates ± standard deviation (*\( p < 0.05 \))
Long non-coding RNA H19 regulates proliferation of ovarian granulosa cells via STAT3 in polycystic ovarian syndrome

Figure 4. A – Cell Counting Kit 8 (CCK-8) assay showing the viability of the normal (NC) and Si-STAT3 transfected KGN cells. Acridine orange/ethidium bromide (AO/EB) (B) and Annexin V/propidium iodide (PI) staining (C) of the NC and Si-STAT3 transfected KGN cells. The values represent the mean of 3 replicates ± standard deviation (*p < 0.05)
was suppressed (Figure 1 C). It was revealed that silencing of lncRNA H19 expression in KGN cells resulted in a significant decline in cell viability (Figure 1 D). AO/EB staining showed that suppression of lncRNA H19 led to apoptosis of KGN cells (Figure 2 A). Annexin V/PI revealed that the apoptotic KGN cell percentage increased from 1.77% to 28.15% upon lncRNA H19 silencing in the KGN cells (Figure 2 B). Moreover, lncRNA H19 suppression led to enhancement of Bax and caspase-3, which was also accompanied by a depletion of Bcl-2 (Figure 2 C).

Expression of LncRNA H19 was regulated by STAT3

Promoter analysis of the lncRNA H19 by MatInspector software revealed the presence of the GAS binding site for STAT3 (Figure 3 A). Therefore, the expression of STAT3 was suppressed in KGN cells to examine its impact on the expression of lncRNA H19. The suppression of STAT3 in KGN cells was validated by western blot analysis (Figure 3 B). The results showed that silencing of STAT3 in KGN cells also resulted in suppression of lncRNA H19 expression (Figure 3 C). Moreover, silencing of STAT3 expression also caused a decline in the viability of the KGN cells (Figure 4 A). The STAT3 silencing mediated inhibition of KGN cell viability was also found to be due to the induction of apoptotic cell death as evident from the AO/EB and Annexin V/PI staining (Figures 4 B, C).

LncRNA H19 and STAT3 acted synergistically in PCOS

To determine whether suppression of both STAT3 and H19 exhibits synergistic effects on the viability of KGN cells, the KGN cells were co-transfected with Si-H19 and Si-STAT3 constructs. It was revealed that growth inhibitory effects of Si-H19 and STAT3 were more significant together than individually, suggestive of synergistic effects (Figure 5).

Discussion

Polycystic ovarian syndrome is one of the prevalent endocrine syndromes in women. It affects 10% of child-bearing women and is one of the causes of infertility in women. LncRNAs have been shown to be associated with the development of several diseases [24, 25]. However, the role of lncRNA H19 has not been explored in PCOS. This study explored the role and therapeutic potential of lncRNA H19 in PCOS for the first time. The expression of H19 was found to be up-regulated in PCOS ovarian tissues. These results were in agreement with previous investigations wherein lncRNAs have been reported to be dysregulated in PCOS ovaries [9, 10]. The results of the present study showed that lncRNA H19 regulates proliferation of ovarian granulosa cells. Silencing of lncRNA causes a significant decline in the viability of KGN ovarian granulosa cells via induction of apoptosis. Several studies carried out previously have also indicated the growth inhibitory role of lncRNA H19. It has been reported to cause significant inhibition of the growth of trophoblasts by modulating the expression of DDX3X [26]. LncRNA H19 also interacts with microRNA-140 to suppress the growth of glioma [27]. In yet another study, it was shown to suppress the growth and proliferation of the cervical cancer cells [28]. A previously carried out study indicated an interaction between lncRNA H19 and STAT3 [29]. Therefore, we also analyzed the promoter of lncRNA H19, which revealed the presence of the STAT3 binding site, indicating that STAT3 might be regulating the expression of lncRNA H19. It was further found that suppression of STAT3 caused a significant decline in the expression of lncRNA H19. Moreover, silencing of STAT3 resulted in the apoptotic cell death of KGN cells in a similar way as that of H19 silencing. To ascertain whether STAT3 and H19 have synergistic effects on the growth of KGN cells, Si-H19 and Si-STAT3 were co-transfected into KGN cells, and interestingly, it was found that the effects of lncRNA H19 and STAT3 were more profound when combined than individually. To sum up, this study will reinforce further studies on lncRNAs to explore their potential for the treatment of PCOS.

In conclusion, the findings of the present study revealed that lncRNA-H19 was aberrantly upregulated in PCOS ovarian tissues and granulosa cells, and regulated their growth by interacting with STAT3. Taken together, the evidence suggests that lncRNAs may prove to be a therapeutic target for the management of PCOS and warrants further investigation.
Acknowledgments
The study was supported by funding from Shaanxi Health and Family Planning Research Fund (No: 2016D076), and Yanan Science and Technology Project (No: 2016HM-04-06).

Conflict of interest
The authors declare no conflict of interest.

References
1. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304-51.
2. Li Y, Zhao W, Wang H, et al. Silencing of IncRNA steroid receptor RNA activator attenuates polycystic ovary syndrome in mice. Biochimie 2019; 157: 48-59.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
4. Lau E. Non-coding RNA: zooming in on lncRNA functions. Nat Rev Genet 2014; 15: 574-5.
5. Hung T, Chang HY. Long non-coding RNA in genome regulation: prospects and mechanisms. RNA Biol 2010; 7: 582-5.
6. Li H, Yu B, Li J, et al. Overexpression of IncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget 2014; 5: 2318-29.
7. Kim HI, Lee DW, Yim GW, et al. Long non-coding RNA HOTAIR is associated with human cervical cancer progression. Int J Oncol 2015; 46: 521-30.
8. Wang XM, Liu Y, Fan YX, et al. IncRNA PTSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. Cancer Biol Ther 2018; 19: 590-7.
9. Wang WT, Sun YM, Huang W, et al. Genome-wide long non-coding RNA analysis identified circulating lncRNAs as novel non-invasive diagnostic biomarkers for gynecological disease. Sci Rep 2016; 6: 23343.
10. Huang X, Hao C, Bao H, et al. aberrant expression of long noncoding RNAs in cumulus cells isolated from PCOS patients. J Ass Reprod Genet 2016; 33: 111-21.
11. Li Y, Zhao W, Wang H, et al. Silencing of IncRNA steroid receptor RNA activator attenuates polycystic ovary syndrome in mice. Biochimie 2019; 157: 48-59.
12. Zhao J, Xu J, Wang W, et al. Long non-coding RNA LINC01572: 28 inhibits granulosa cell growth via a decrease in p27(Kip1) degradation in patients with polycystic ovary syndrome. EBioMedicine 2018; 36: 526-38.
13. Liu Z, Hao C, Huang X, et al. Peripheral blood leukocyte expression level of IncRNA steroid receptor RNA activator (SRA) and its association with polycystic ovary syndrome: a case control study. Gynecol Endocrinol 2015; 31: 363-8.
14. Sen A, Prizant H, Light A, Biswas A, et al. Androgens regulate ovarian follicular development by increasing follicle stimulating hormone receptor and microRNA-125b expression. Proc Natl Acad Sci 2014; 111: 3008-13.
15. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers 2016; 2: 16057.
16. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-82.
17. Deng J, Li C, Luo J, Xie J, Peng C, Deng X. MicroRNA-125b controls growth of ovarian granulosa cells in polycystic ovarian syndrome by modulating cyclin B1 expression. Arch Med Sci in press DOI: https://doi.org/10.5114/aoms.2019.85809.
18. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141-6.
19. Naderpour N, Shorakae S, de Courten B, et al. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Human Reprod Update 2015; 21: 560-74.
20. Lo JC, Yang J, Gunderson EP, et al. Risk of type 2 diabetes mellitus following gestational diabetes pregnancy in women with polycystic ovary syndrome. J Diabetes Res 2017; 2017: 5250162.
21. Rotterdam ES/RE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
22. Jiang L, Huang J, Li F, et al. MicroRNA-93 promotes ovarian granulosa cells proliferation through targeting CDKN1A in polycystic ovarian syndrome. J Clin Endocrinol Metab 2015; 100: E729-38.
23. Hua E, Li CH, Chen XG, et al. Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer cells by inducing apoptosis and cell cycle arrest, and inhibiting the RalF/MEK/ERK cascade. Int J Mol Med 2018; 41: 3485-92.
24. Xue X, Yang YN, Zhang A, et al. lncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene 2016; 35: 2746-55.
25. Kim K, Jutooru I, Chadalapaka G, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 2013; 32: 1616-25.
26. Ma Y, Sun N, Sheng F, et al. Long noncoding RNA H19 inhibits the growth and invasion of trophoblasts by inactivating Wnt/beta-catenin signaling via downregulation of DDX3X. Int J Clin Exp Pathol 2017; 10: 6560-7.
27. Zhao H, Peng R, Liu Q, et al. The IncRNA H19 interacts with miR-140 to modulate glioma growth by targeting IASPP. Arch Biochem Biophys 2016; 610: 1-7.
28. Xin H, Li M, Cheng X, et al. Suppression of long non-coding RNA H19 inhibits proliferation, cell migration and invasion in human cervical cancer cells. Trop J Pharm Res 2018; 17: 1249-53.
29. Hofmann P, Sommer J, Theodorou K, et al. Long non-coding RNA H19 regulates proliferation of ovarian granulosa cells via STAT3 in polycystic ovarian syndrome.